Skip to main content
Article
Initial Observations of Cell-Mediated Drug Delivery to the Deep Lung
Cell Transplantation
  • Arun Kumar, University of South Florida
  • Mark Glam, University of South Florida
  • Nagwa El-Badri, University of South Florida
  • Shyam Mohapatra, University of South Florida
  • Edward M Haller, University of South Florida
  • Park Seungjoo, University of South Florida
  • Leslie Patrick, University of South Florida
  • Leigh Nattkemper, University of South Florida
  • Vo Dawn, University of South Florida
  • Don F. Cameron, University of South Florida
Document Type
Article
Publication Date
1-1-2011
Keywords
  • Sertoli cells; Drug delivery; Deep lung
Digital Object Identifier (DOI)
https://doi.org/10.3727/096368910X536491
Abstract

Using current methodologies, drug delivery to small airways, terminal bronchioles, and alveoli (deep lung) is inefficient, especially to the lower lungs. Urgent lung pathologies such as acute respiratory distress syndrome (ARDS) and post-lung transplantation complications are difficult to treat, in part due to the methodological limitations in targeting the deep lung with high efficiency drug distribution to the site of pathology. To overcome drug delivery limitations inhibiting the optimization of deep lung therapy, isolated rat Sertoli cells preloaded with chitosan nanoparticles were use to obtain a high-density distribution and concentration (92%) of the nanoparticles in the lungs of mice by way of the peripheral venous vasculature rather than the more commonly used pulmonary route. Additionally, Sertoli cells were preloaded with chitosan nanoparticles coupled with the anti-inflammatory compound curcumin and then injected intravenously into control or experimental mice with deep lung inflammation. By 24 h postinjection, most of the curcumin load (∼90%) delivered in the injected Sertoli cells was present and distributed throughout the lungs, including the perialveloar sac area in the lower lungs. This was based on the high-density, positive quantification of both nanoparticles and curcumin in the lungs. There was a marked positive therapeutic effect achieved 24 h following curcumin treatment delivered by this Sertoli cell nanoparticle protocol (SNAP). Results identify a novel and efficient protocol for targeted delivery of drugs to the deep lung mediated by extratesticular Sertoli cells. Utilization of SNAP delivery may optimize drug therapy for conditions such as ARDS, status asthmaticus, pulmonary hypertension, lung cancer, and complications following lung transplantation where the use of high concentrations of anti-inflammatory drugs is desirable, but often limited by risks of systemic drug toxicity.

Citation / Publisher Attribution

Cell Transplantation, v. 20, issue 5, p. 609-618

Citation Information
Arun Kumar, Mark Glam, Nagwa El-Badri, Shyam Mohapatra, et al.. "Initial Observations of Cell-Mediated Drug Delivery to the Deep Lung" Cell Transplantation Vol. 20 Iss. 5 (2011) p. 609 - 618
Available at: http://works.bepress.com/edward_haller/29/